New light therapy for intermediate age-related macular degeneration
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Injuries & trauma clinical trials.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older
- You have intermediate AMD (Grade AREDS 3)
- Both of your eyes can be treated in this study
- You are willing to follow the study rules and come for follow-up visits
- You will keep your current diet and lifestyle habits as much as possible during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This trial tests whether a special laser (photobiomodulation) can help slow or improve vision loss from reticular pseudodrusen, a specific type of retinal damage seen in age-related macular degeneration. The laser delivers safe light energy to stimulate healing in the eye.
This trial tests if repeated low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a condition that causes gradual vision loss. The therapy uses red light to potentially slow or improve vision problems.
This trial tests a new approach to improve vision in people with end-stage age-related macular degeneration (AMD). It aims to help those whose vision has dropped to a moderate or severe level, even with glasses, and who are not contact lens wearers.
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
Hear when a new Intermediate AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.